Rights and permissions
About this article
Cite this article
Dasatinib: a once-daily option for imatinib-resistant CML. Inpharma Wkly. 1573, 15–16 (2007). https://doi.org/10.2165/00128413-200715730-00039
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200715730-00039